NCT07373067 · Phase 1 · NOT YET RECRUITING
Repeat Intracerebroventricular Injections of RB-ADSC in Subjects Previously Treated in RBI Protocol RB-ADSC-02
This early trial tests repeat doses of RB-ADSC, a cell-based biological product, given into the fluid-filled spaces of the brain through an implanted port. It mainly measures safety, with some early checks on memory and thinking. It is a Phase 1b extension, an early safety step, not proof it works and not approved.
You may qualify if
- Successful completion of the Phase 1 single dose administration study of RB-ADSC, Protocol RB-ADSC-02.
- Written informed consent to participate in this Phase 1b Extension Study either provided by the participant or a legal representative
- The participant must have a relative/caregiver who is alert for possible side effects.
- The caregiver must separately meet the specified inclusion/exclusion criteria for caregivers for this Phase 1b Extension Study.
You're excluded if
- Participant experienced treatment related SAE or DLT in Protocol RB-ADSC-02
- Participants who, in the opinion of the Investigator, are unsuitable for this Phase 1 Extension Study
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-26